Levetiracetam Hospira (Levetiracetam)

Levetiracetam is an anticonvulsant that targets seizure activity in the central nervous system.

• Partial-onset seizures: Reduces frequency of focal seizures when used as add‑on therapy.
• Myoclonic seizures: Decreases myoclonic jerks in patients with juvenile myoclonic epilepsy.
• Primary generalized tonic‑clonic seizures: Lowers occurrence of generalized convulsive seizures as adjunctive treatment.
• Status epilepticus: Provides rapid intravenous control of ongoing seizures unresponsive to first‑line agents.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, decreasing neuronal excitability and limiting the release of excitatory neurotransmitters such as glutamate. By stabilizing synaptic transmission, the drug helps prevent the abnormal electrical discharges that underlie epileptic seizures. The precise downstream pathways remain under investigation, but the overall effect is a reduction in hypersynchronous neuronal firing.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: Sensation of light‑headedness or unsteadiness.
• Fatigue: Generalized tiredness or lack of energy.
• Nausea: Stomach upset often without vomiting.
• Irritability: Mood changes or increased agitation.

Serious or Rare Side Effects

• Severe allergic reaction: Rash, swelling, or anaphylaxis.
• Mood or behavioral changes: Depression, suicidal thoughts, or aggression.
• Blood abnormalities: Decreased white blood cells or platelets.
• Respiratory depression: Marked slowing of breathing, especially with concomitant depressants.

When using Levetiracetam, clinicians should observe several precautionary measures to ensure patient safety.

• Renal function: Adjust dosing in patients with impaired clearance.
• Pregnancy: Use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant CNS depressants: Monitor for additive sedation or respiratory effects.
• Behavioral monitoring: Observe for new or worsening mood disturbances.
• Discontinuation: Do not stop abruptly; taper under medical guidance to avoid seizure exacerbation.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Carbamazepine: May reduce levetiracetam plasma levels, decreasing effectiveness.
• Phenobarbital: Similar enzyme‑inducing effect that can lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely)

• Sedative agents (e.g., benzodiazepines, opioids): May enhance central nervous system depression.
• Antidepressants (e.g., SSRIs): Potential for increased behavioral side effects.
• Immunosuppressants (e.g., tacrolimus): Possible alteration of drug levels; monitor concentrations.